Form 4: Aquestive CPO Peter Boyd Receives 20,000 Restricted Shares

Aquestive Therapeutics' Chief People Officer, Peter E. Boyd, acquired 20,000 shares of common stock as restricted stock, vesting over three annual installments.

Summary

• Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, Inc. (AQST), acquired 20,000 shares of common stock.
• The transaction occurred on December 4, 2025.
• The shares were acquired at a price of $0, indicating a grant of restricted stock.
• Following this transaction, Boyd beneficially owns 288,323 shares of common stock.
• The restricted stock vests in three annual installments: 25% in the first, 25% in the second, and 50% in the third installment.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a standard executive equity grant, which is generally positive for aligning management incentives with shareholder interests, but does not contain significant new operational or financial news.

Positives

• The grant of 20,000 restricted shares to a key executive, Peter E. Boyd, aligns management incentives with long-term shareholder value.
• The vesting schedule, with 50% vesting in the third installment, encourages long-term retention and performance.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent acquisition.

Future Outlook

The vesting schedule for the restricted stock, extending over three annual installments, implies a long-term commitment and incentive structure for the Chief People Officer, aligning with future company performance.

Industry Context

Equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industry, like Aquestive Therapeutics, to attract, retain, and incentivize talent. Such grants align executive interests with long-term shareholder value, particularly important in industries with long development cycles and high R&D costs.

Comparison to Industry Standards

• The grant of restricted stock at a $0 price is a common form of equity compensation for executives across various industries, including biotech, aligning with typical compensation structures seen at companies like BioNTech or Moderna for their senior leadership.
• A multi-year vesting schedule (e.g., three annual installments) is standard practice to ensure executive retention and incentivize sustained performance, comparable to vesting schedules observed at peer companies such as Jazz Pharmaceuticals or Acadia Pharmaceuticals.

Corporate Governance

Related Party Transactions

• This transaction is a direct compensation grant from Aquestive Therapeutics, Inc. (issuer) to Peter E. Boyd (Chief People Officer and reporting person), which constitutes a related party transaction in the context of executive compensation.

Stakeholder Impact

• **Shareholders:** The grant of restricted stock to a key executive can be viewed positively as it aligns management's long-term interests with shareholder value creation. However, it also represents potential future dilution as shares vest.
• **Employees:** This grant is specific to a senior officer and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• The restricted stock will vest in three annual installments, with 25% on the first, 25% on the second, and 50% on the third installment.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive, which is a standard practice for aligning management incentives. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for significant re-evaluation.

Keywords

Aquestive Therapeutics, AQST, Peter E. Boyd, Chief People Officer, Restricted Stock, Equity Grant, Insider Transaction, Form 4, Compensation, Stock Vesting